Clinical trials: Histological Response
Myeloid Leukemia, Acute
Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments
This study aims to analyze patients with mutated FLT3 AML treated with specific therapy by means of molecular characterization methods, to identify the presence of clones and subclones at onset and to be able to follow their…
- Trial name
- CLEV-LAM-2022 (NCT06764459)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Melanoma, Renal Cancer
Microbiome Immunotherapy Toxicity and Response Evaluation
This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer.
- Conditions
- Melanoma, Renal Cancer, Lung Cancer
- Trial name
- NCT04107168
- Testing
- Nivolumab, Pembrolizumab, Ipilimumab
- Where
- 13 sites in United Kingdom
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- CCTU- Cancer Theme
Renal Cell Carcinoma
Neoadjuvant Pazopanib in Renal Cell Carcinoma
This study will be a single arm phase II clinical trial of 8 weeks of daily, oral neo-adjuvant pazopanib prior to nephrectomy in 39 evaluable patients with histologically confirmed localized renal cell carcinoma (RCC).
- Trial name
- NCT01361113
- Testing
- Pazopanib
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Hodgkin's Lymphoma
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
This 2 arm study will compare the efficacy and safety of the standard chemotherapy of the East German Study Group for Hematology and Oncology versus standard chemotherapy plus MabThera (375mg/m2 iv, once monthly for 8 cycles) in…
- Trial name
- NCT00269113
- Testing
- rituximab [MabThera/Rituxan], Standard chemotherapy
- Where
- 33 sites in Germany
- Volunteers
- 360 people
- Sponsor
- Hoffmann-La Roche
Moderate and Severe RheumatoId Arthritis
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
The purpose of this study is to initially access the safety and effectivity of RC18 combined with methotrexate (MTX) in comparison with the use of methotrexate alone in participants with moderate to severe Rheumatoid Arthritis…
- Trial name
- NCT03016013
- Testing
- RC18 160 mg plus MTX
- Where
- China
- Volunteers
- 479 people
- Sponsor
- RemeGen Co., Ltd.
Metastatic Melanoma
Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment
In-transit metastases occur in approximately 3% of melanoma patients, can be very symptomatic and the survival in this group may be prolonged. In-transit melanoma metastases are often confined to a limb.
- Trial name
- ILI (NCT01920516)
- Testing
- Melphalan
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- International Group of Endovascular Oncology
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides
Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides
This is a single-arm, non-randomized feasibility study designed to find out if the laser light-based imaging test called Biodynamic imaging (BDI) can correctly predict the cutaneous T-cell lymphoma mycosis fungoides (MF) cancer…
- Trial name
- BDI (NCT03789864)
- Testing
- Biodynamic imaging (BDI) of mycosis fungoides
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Indiana University
Adrenocortical Carcinoma, Adrenocortical Cancer
Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)
Background: Adrenocortical cancer (ACC) is a rare tumor. The prognosis is very poor for people with advanced stages of ACC. Some people may live with ACC for years; others live for just months.
- Trial name
- NCT04447014
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Crohn Disease (CD), Ulcerative Colitis (UC)
IBD Biomarker Discovery and Validation Platform
The goal of this observational study is to establish a multicenter prospective clinical and biospecimen platform for biomarker discovery and validation in inflammatory bowel disease, including Crohn's disease and ulcerative…
- Conditions
- Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Diseases (IBD)
- Trial name
- IBD-BIOP (NCT07686406)
- Where
- 2 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma (HNSCC)
Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET
This is a single-centre, non-randomized, two-stage design, proof-of-concept study evaluating the radiolabelled PARP inhibitor [18F]-olaparib als potential tracer for imaging of tumour PARP expression by PET.
- Trial name
- [18F]-olaparib (NCT06482307)
- Testing
- [18F]-olaparib PET scan
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
Head and Neck Cancer
A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC
RATIONALE: Gathering disease-related information from medical charts of patients with primary head and neck cancer who have undergone neck dissection after complete response to chemotherapy and radiation therapy may help doctors…
- Trial name
- NCT00483821
- Testing
- medical chart review
- Where
- 3 sites in United States
- Volunteers
- 165 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hodgkin Lymphoma
Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision.
Recently published studies demonstrated very high event free survival for patients with a normal interim PET/CT and a high hazard ratio for progression of an interim positive (pathological)study.
- Trial name
- NCT00392314
- Testing
- PET/CT post 2 cycles of chemotherapy
- Where
- Israel
- Volunteers
- 365 people
- Sponsor
- Rambam Health Care Campus
Hepatocellular Carcinoma
Multimodal Ultrasound and Hepatocellular Response to Local Treatments
Consecutive patients with HCC who should undergo to locoregional treatments (ablation or trans-arterial chemoembolization) according to international guidelines will be enrolled.
- Trial name
- NCT05987514
- Testing
- multimodal ultrasound
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neuroendocrine Tumors, Carcinoid Tumors
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
This study plans to demonstrate the safety and efficacy of [68Ga]-DOTA-tyr3-Octreotide ([68Ga]-DOTATOC) as an accurate imaging technique for diagnosis, staging, and monitoring of response to treatment in patients with…
- Trial name
- NCT02359500
- Testing
- 68Ga-DOTATOC PET
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Lale Kostakoglu
Acute Myeloid Leukemia
Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML
This trial compares outcome of two treatment strategies for patients with high-risk AML who failed to achieve or maintain a complete remission with standard therapy. Patients will be randomized between two strategies.
- Trial name
- ETAL3-ASAP (NCT02461537)
- Testing
- HAM, LDAC and/or Mitoxantrone
- Where
- 18 sites in Germany
- Volunteers
- 281 people
- Sponsor
- DKMS gemeinnützige GmbH
Diffuse Large B Cell Lymphoma
18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma
Open-label, multicenter, uncontrolled and non-randomized study comparing 18F-FDG PET-Scan and diffusion MRI in the assessment of the early therapeutic response of Diffuse Large B-Cell Lymphoma.
- Trial name
- LYMPHODTECT (NCT03121456)
- Testing
- 18F-FDG PET SCAN, MRI DIFFUSION
- Where
- France
- Volunteers
- 74 people
- Sponsor
- Centre Antoine Lacassagne
Hepatocellular Carcinoma
Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 7th most common cancer worldwide but is the 4th deadliest, because diagnosis tend to be late and current systemic therapies are poorly efficacious.
- Trial name
- EMPHASIS (NCT05516628)
- Testing
- Surgical Resection, Adjuvant Atezolizumab-Bevacizumab Therapy
- Where
- 6 sites in Singapore
- Volunteers
- 30 people
- Sponsor
- National Cancer Centre, Singapore
Chronic Myeloid Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
A multicenter, open label cohort Phase 1 dose finding study to evaluate tolerability, safety, pharmacokinetics and preliminary efficacy of PF-114 for oral administration in adult patients with Philadelphia chromosome positive…
- Trial name
- NCT02885766
- Testing
- PF-114
- Where
- 3 sites in Russia
- Volunteers
- 65 people
- Sponsor
- Fusion Pharma LLC
Head and Neck Cancer
Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898430
- Testing
- DNA Microarray analysis, MALDI-TOF mass spectrometry, DNA microarray and MALDI-TOF mass spectrometry
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cytokine Release Syndrome, Neoplasms
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
Background: Drugs or cell therapies to treat cancer can sometimes cause cytokine release syndrome (CRS). That is, the body makes too many cytokines after treatment. Cytokines are proteins that play a role in the immune system.
- Conditions
- Cytokine Release Syndrome, Neoplasms, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Trial name
- NCT07499128
- Testing
- TempTraq, VitalTraq
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.